Given that microsatellite instability, BRAF, and RAS mutation status are routinely tested﻿ for colorectal cancers (CRC), studying SARIFA’s additional prognostic value within these molecular subgroups is crucial. This evidence concerns the gene BRAF and colorectal carcinoma.